Jeffrey M. Lynch

Jeffrey M. Lynch

Auto-generated profile, based on publicly available information

Jeffrey M. Lynch

Ophthalmology, Novartis Institutes for Biomedical Research, United States

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2008 in Biochemistry
Verified
Journal Article
Closed access
YQYuanyuan Qiu
Yuanyuan Qiu
JLJeffrey Lynch
Jeffrey Lynch
LGLei Guo
Lei Guo
BYBogdan Yatsula
Bogdan Yatsula
APArchibald S. Perkins
Archibald S. Perkins
Marek MichalakMarek Michalak
Marek Michalak

1 December 2018 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
JLJeffrey M. Lynch
Jeffrey M. Lynch
BLBing Li
Bing Li
PKParvaneh Katoli
Parvaneh Katoli
CXChuanxi Xiang
Chuanxi Xiang
BLBarrett Leehy
Barrett Leehy
ACAmy Chen
Amy Chen
Myocilin (MYOC) was discovered more than 20 years ago and is the gene whose mutations are most commonly observed in individuals with glaucoma. Despite extensive research efforts, the function of wild-type (wt) MYOC has remained elusive and how mutant MYOC is linked to glaucoma is unclear. Mutant MYOC is believed to be misfolded within the endoplasmic reticulum (ER), and under normal physiological conditions misfolded MYOC should be retro-translocated to the cytoplasm for degradation. To better understand mutant MYOC pathology, we CRISPR-engineered a rat to have a MYOC Y435H substitution which is the equivalent of the pathologic human MYOC Y437H mutation. Using this engineered animal model, we discovered that the chaparone αB-crystallin (CRYAB) is a MYOC-binding partner and that co-expression of these two proteins increases protein aggregates. Our results suggest that the misfolded mutant MYOC aggregates with cytoplasmic CRYAB and thereby compromises protein clearance mechanisms in trabecular meshwork cells and this process represents the primary mode of mutant MYOC pathology. We propose a model by which mutant MYOC causes glaucoma, and we propose that therapeutic treatment of patients having a MYOC mutation may focus on disrupting the MYOC-CRYAB complexes.

5 November 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JLJeffrey M Lynch
Jeffrey M Lynch
ADAndrew J Dolman
Andrew J Dolman
CGChenying Guo
Chenying Guo
KDKatie Dolan
Katie Dolan
CXChuanxi Xiang
Chuanxi Xiang
GPGanesh Prasanna
Ganesh Prasanna
Myocilin (MYOC) is the gene with mutations most common in glaucoma. In the eye, MYOC is in trabecular meshwork, ciliary body, and retina. Other tissues with high MYOC transcript levels are skeletal muscle and heart. To date, the function of wild-type MYOC remains unknown and how mutant MYOC causes high intraocular pressure and glaucoma is ambiguous. By investigating mutant MYOC in a non-ocular tissue we hoped to obtain novel insight into mutant MYOC pathology. For this study, we utilized a transgenic mouse expressing human mutant MYOC Y437H protein and we examined its skeletal (gastrocnemius) muscle phenotype. Electron micrographs showed that sarcomeres in the skeletal muscle of mutant CMV-MYOC-Y437H mice had multiple M-bands. Western blots of soluble muscle lysates from transgenics indicated a decrease in two M-band proteins, myomesin 1 (MYOM1) and muscle creatine kinase (CKM). Immunoprecipitation identified CKM as a MYOC binding partner. Our results suggest that binding of mutant MYOC to CKM is changing sarcomere ultrastructure and this may adversely impact muscle function. We speculate that a person carrying the mutant MYOC mutation will likely have a glaucoma phenotype and may also have undiagnosed muscle ailments or vice versa, both of which will have to be monitored and treated.

1 July 2018 in Protein Expression and Purification
Verified
Journal Article
Closed access
PKParvaneh Katoli
Parvaneh Katoli
AGAdarsh Godbole
Adarsh Godbole
MRMichael J. Romanowski
Michael J. Romanowski
KCKirk Clark
Kirk Clark
EMErik Meredith
Erik Meredith
JLJeffrey M. Lynch
Jeffrey M. Lynch